Organisation paid for research Program year 2024 Source: CMS Open Payments

Fresenius Management Services

Neither a doctor nor a teaching hospital

Research payments

$1,443,021

415 payments

Through program year 2024, Fresenius Management Services is reported as receiving $1,443,021 in research payments, across 415 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$3,476	1
2023	Research	$225,672	37
2022	Research	$408,664	164
2021	Research	$773,885	209
2020	Research	$28,836	3
2019	Research	$2,488	1

Breakdown

Who paid Research payments · program years 2019–2024

GlaxoSmithKline, LLC. $1,409,524 411 payments
Takeda Pharmaceuticals U.S.A., Inc. $33,497 4 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 3 Randomized, Open-Label (Sponsor-Blind), Active-Controlled, P $1,190,701 321 payments
A 52-Week Open-Label (Sponsor-Blind), Randomized, Active-Controlled, P $218,823 90 payments
TAK-079-1006A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy $33,497 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.